Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Loading network data...

Showing 5 of 5 trials

Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis

Role: collaborator

Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial

Role: collaborator

Transperineal Laser Ablation for Treatment of Benign Prostatic Obstruction

Role: collaborator

Transperineal Laser Ablation for Focal Treatment of Prostate Cancer

Role: collaborator

Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results

Role: lead

All 5 trials loaded